Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C18H26FNO4 |
Molar mass | 339.407 g·mol−1 |
3D model ( JSmol) | |
| |
|
Edivoxetine ( INN; code name LY-2216684) is a drug which acts as a selective norepinephrine reuptake inhibitor and was under development by Eli Lilly for attention-deficit disorder (ADD) and as an antidepressant treatment. [1] [2] It was in phase III clinical trials in 2012 for major depressive disorder, but failed to get approval. [1] [3]
In a study published in 2010, edivoxetine succeeded to prove superiority over placebo, as measured by Hamilton Depression Rating Scale. However, effectiveness could be observed using the Self-Rated Quick Inventory of Depressive Symptomatology. [4]
In a study published in 2011, using the Montgomery–Åsberg Depression Rating Scale and the Sheehan Disability Scale, edivoxetine showed superiority over placebo, with higher response and remission rates. [5]
In December 2013, Eli Lilly announced that the clinical development of edivoxetine will be stopped due to lack of efficacy compared to SSRI alone in three separate clinical trials. [6]
Side effects significantly associated with edivoxetine are headache, nausea, constipation, dry mouth and insomnia. [4]
The above-mentioned studies report increases of the cardiac rhythm, and one also increases of diastolic and systolic blood pressures. [4] [5]
{{
cite journal}}
: Unknown parameter |agency=
ignored (
help)
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C18H26FNO4 |
Molar mass | 339.407 g·mol−1 |
3D model ( JSmol) | |
| |
|
Edivoxetine ( INN; code name LY-2216684) is a drug which acts as a selective norepinephrine reuptake inhibitor and was under development by Eli Lilly for attention-deficit disorder (ADD) and as an antidepressant treatment. [1] [2] It was in phase III clinical trials in 2012 for major depressive disorder, but failed to get approval. [1] [3]
In a study published in 2010, edivoxetine succeeded to prove superiority over placebo, as measured by Hamilton Depression Rating Scale. However, effectiveness could be observed using the Self-Rated Quick Inventory of Depressive Symptomatology. [4]
In a study published in 2011, using the Montgomery–Åsberg Depression Rating Scale and the Sheehan Disability Scale, edivoxetine showed superiority over placebo, with higher response and remission rates. [5]
In December 2013, Eli Lilly announced that the clinical development of edivoxetine will be stopped due to lack of efficacy compared to SSRI alone in three separate clinical trials. [6]
Side effects significantly associated with edivoxetine are headache, nausea, constipation, dry mouth and insomnia. [4]
The above-mentioned studies report increases of the cardiac rhythm, and one also increases of diastolic and systolic blood pressures. [4] [5]
{{
cite journal}}
: Unknown parameter |agency=
ignored (
help)